Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD urged to overturn decision on flunixin
Flunixin is a common analgesic used in horses with colic

Product suspended over potential risk to humans

Leading equine veterinary association BEVA is urging the Veterinary Medicines Directorate (VMD) to overturn its decision to suspend the sale of flunixin.

Flunixin is a common analgesic used in horses with colic, as well as for those undergoing surgery and other conditions. On Thursday (26 July), the VMD suspended the product after the Committee for Medicinal Products for Veterinary Use (CVMP) said that a solvent in the injectable formulation - diethanolamine - could pose a risk to humans.

Now BEVA is calling on the VMD to overturn this decision in horses not destined for the human food chain, to reduce the potential impact on equine welfare. It argues that the decision had been made without warning or consultation with the veterinary profession.

“BEVA is fully supportive of all attempts to promote food safety, however, flunixin is widely viewed as the gold-standard painkiller in horses and is commonly used in horses undergoing both elective and emergency surgery, for the crippling pain associated with laminitis and for severe forms of colic,” said BEVA president Jonathan Pycock.

“BEVA is calling on the VMD to immediately enable limited batch release of flunixin for use in horses not destined for the human food chain in the interests of animal welfare. The equine veterinary profession has always been open to consultation with the VMD on a range of important matters relating to responsible medicine use, antibiotic resistance, horse identification, passports and the horse meat issue.

“BEVA is perplexed as to why the VMD failed to consult with the equine veterinary industry on the animal welfare impact of withdrawing such an important drug.”

Used widely throughout the veterinary industry, flunixin is the only medicine licensed for the treatment of sepsis. BEVA states that no recall notices have been issued and therefore veterinary surgeons may continue to prescribe medicines that are in stock.

A disruption to the supply chain, however, could lead to shortages of this medicine in clinical practic, it said. 

Image (C) Redwings Horse Sanctuary

Become a member or log in to add this story to your CPD history

Submissions open for BSAVA Clinical Research Abstracts 2026

News Story 1
 The BSAVA has opened submissions for the BSAVA Clinical Research Abstracts 2026.

It is an opportunity for applicants to present new research on any veterinary subject, such as the preliminary results of a study, discussion of a new technique or a description of an interesting case.

They must be based on high-quality clinical research conducted in industry, practice or academia, and summarised in 250 words.

Applications are welcome from vets, vet nurses, practice managers, and students.

Submissions are open until 6 March 2026. 

Click here for more...
News Shorts
Survey seeks ruminant sector views on antimicrobial stewardship

A new survey is seeking views of people working in the UK ruminant sector on how to tackle the challenge of demonstrating responsible antibiotic stewardship.

Forming part of a wider, collaborative initiative, the results will help identify the types of data available so that challenges with data collection can be better understood and addressed.

Anyone working in the UK farming sector, including vets and farmers,is encouraged to complete the survey, which is available at app.onlinesurveys.jisc.ac.uk